Protein may help control cancer cells
The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 245 entries already.
The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.
Sanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.
Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
Dutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
Danish Novo Nordisk is moving out of the diabetes space and taking over Prothena’s ATTR amyloidosis programme – including a Phase II-ready immunotherapy.
Sanofi is shelling out US$1bn for a license granting the French pharma company access to a potential multiple myeloma treatment.
French biopharma company NFL Biosciences has raised €5m following its IPO at Euronext Growth Paris.
With a €20m financing round under its belt, Promethera Therapeutics is poised to start its Phase IIb study for its stem cell therapy treating liver failure.
The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.
Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based free trade.

